查看购物车
  • Traditional Chinese
  • English
2021-2031年阿兹海默症药物市场规模及预测、全球及区域份额、趋势和成长机会分析报告涵盖范围：按药物类别和最终用户（医院药房、零售药房和线上药房）划分
市场调查报告书
商品编码
1858585

2021-2031年阿兹海默症药物市场规模及预测、全球及区域份额、趋势和成长机会分析报告涵盖范围：按药物类别和最终用户（医院药房、零售药房和线上药房）划分

Alzheimer's Drugs Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class and End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
出版日期: | 出版商: The Insight Partners | 英文 215 Pages | 订单完成后即时交付

价格

阿兹海默症药物市场预计将从2024年的82.4亿美元成长到2031年的263.7亿美元，2025年至2031年间的复合年增长率（CAGR）预计为13.6%。人口老化、阿兹海默症患者病率上升以及诊断和早期检测技术的进步是推动阿兹海默症药物市场规模扩张的重要因素。然而，疾病改善疗法的高昂成本阻碍了阿兹海默症药物市场的发展。

公私合作及经费支持能够有效整合政府机构、学术中心、製药公司和慈善基金会的资源，加速有效疗法的研发。美国国立卫生研究院 (NIH) 的「加速药物研发伙伴关係-阿兹海默症」（AMP-AD 2.0）计画已吸引大量资源，推动阿兹海默症的研究。该计画整合了 NIH 超过 6,100 万美元的公共投资，以及卫材 (Eisai) 和武田 (Takeda) 等製药公司的投资。该计画旨在促进资料和精准医疗策略的开放共享，加速生物标记的发现和治疗标靶的验证。诸如 BrightFocus 和 Part the Cloud 等慈善项目已投入数百万美元用于早期研究，以支持具有前瞻性的项目，这些项目已从风险投资和製药公司合作等多个管道获得超过 10 亿美元的资金。在州一级，拟建的德克萨斯州痴呆症预防与研究所（DPRIT）将在十年内投入高达30亿美元用于痴呆症研究，促进合作，从而推动当地生物技术的发展和临床突破。此外，大型製药公司和生技公司之间的合作日益增多，例如渤健（Biogen）与卫材（Eisai）合作，共同开发和销售阿兹海默症疗法，汇集资源和能力，加快产品进入市场的速度。这些公私合作项目降低了财务风险，加强了资源共享，降低了药物研发的风险，并缩短了研发週期。在商业层面，这些计画丰富了阿兹海默症药物的研发管线，刺激了生物技术和製药公司的投资，并增强了监管机构和公众对新药的信任。这些合作关係和资金流入正在加速疾病改善疗法的研发，并支撑着一个更创新驱动的阿兹海默症药物市场。

基于最终用户的洞察

根据最终用户，阿兹海默症药物市场可分为医院药房、零售药房和线上药房。 2024年，医院药局占据了最大的阿兹海默症药物市场。尤其是在以住院治疗为主要诊断和治疗启动方式的地区，医院药房负责分发和管理阿兹海默症药物。由于阿兹海默症的治疗管理十分复杂，需要神经科医生或老年科医生的专业诊治，因此医院药房在处方、配药以及为患者和护理人员提供治疗方案建议方面发挥着至关重要的作用。医院药房阿兹海默症药物的销售受到报销政策和不断变化的治疗建议的影响。医院仍将胆碱酯酶抑制剂（ChEI）作为轻度至中度阿兹海默症的第一线对症治疗药物。由于其疗效和耐受性良好，多奈哌齐（安理申）作为全球处方量最大的胆碱酯酶抑制剂，已被纳入医院的处方集。利伐斯的明具有灵活的给药方式，尤其适用于便于病人监测的医院环境。它有口服胶囊和透皮贴片两种剂型。医院药局透过提供用药咨询、依从性监测和副作用管理等服务来提升价值——这些服务对于阿兹海默症治疗至关重要。此类服务使医院药房的产品和服务区别于零售药房，并有助于改善患者预后，从而可能推动对特定剂型（例如，利伐斯的明贴剂以提高依从性）的需求，进而促进阿兹海默症药物市场的成长。

在编写阿兹海默症药物市场报告时，参考的主要和次要来源包括世界卫生组织和美国医疗保险。

目录

第一章：引言

第二章：执行概要

  • 分析师市场展望
  • 市场吸引力

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：
  • 假设和局限性

第四章：阿兹海默症药物市场概况

  • 概述
  • PEST分析

第五章：阿兹海默症药物市场－关键市场动态

  • 阿兹海默症药物市场—关键市场动态
  • 市场驱动因素
    • 人口老化与阿兹海默症患者病率上升
    • 改进诊断和早期检测
  • 市场限制
    • 疾病修饰疗法（DMTs）成本高昂
  • 市场机会
    • 联合疗法和辅助治疗
  • 未来趋势
    • 公私合作与资金成长
  • 驾驶员和安全带的影响：

第六章：阿兹海默症药物市场－全球市场分析

  • 2021-2031年阿兹海默症药物市场收入
  • 阿兹海默症药物市场预测分析

第七章：阿兹海默症药物市场分析－依药物类别划分

  • 胆碱酯酶抑制剂
  • NMDA受体拮抗剂
  • 复方药物
  • 其他的

第八章：阿兹海默症药物市场分析－以最终用户划分

  • 医院药房
  • 零售药局
  • 网路药局

第九章：阿兹海默症药物市场—地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：竞争格局

  • 关键参与者热力图分析
  • 公司市占率分析，2024 年

第十一章：行业概况

  • 概述
  • 新产品开发与审批
  • 合作关係
  • 其他商业策略

第十二章：公司简介

  • Novartis AG
  • Daiichi Sankyo Co Ltd
  • Johnson & Johnson
  • Pfizer Inc
  • Merck & Co Inc
  • Biogen Inc
  • Merz Pharma GmbH & Co KGaA
  • Eli Lilly and Co
  • Otsuka Pharmaceuticals Co Ltd
  • AbbVie Inc

第十三章：附录

Product Code: TIPRE00015800

The Alzheimer's drugs market size is expected to grow from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031; it is projected to register a CAGR of 13.6% during 2025-2031. The aging population & rising Alzheimer's prevalence, and improved diagnostics & early detection are noteworthy factors contributing to the expansion of the Alzheimer's drugs market size. However, the high cost of disease-modifying therapies hinders the Alzheimer's drugs market.

Public-private partnerships and funding leverage the resources of government organizations, academic centers, pharmaceutical firms, and philanthropic foundations to speed up the creation of effective treatments. The US National Institutes of Health (NIH)'s Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD 2.0) has attracted a substantial number of resources to drive research on Alzheimer's. This initiative integrates more than US$61 million of public investment from the NIH with investment from pharmaceutical firms like Eisai and Takeda. This project promotes open sharing of data and precision medicine strategies, accelerating biomarker discovery and validation of therapeutic targets. Philanthropic initiatives like BrightFocus and Part the Cloud have invested millions in early-stage research, backing forward-thinking projects which have secured more than a billion dollars in funding from multiple sources, ranging from venture capital to pharma partnerships. At the state level, the proposed Texas Dementia Prevention and Research Institute of Texas (DPRIT) would commit up to US$3 billion over ten years to dementia research, fostering collaborations that might spur local biotech expansion and clinical breakthroughs. Furthermore, partnerships among big pharma and biotechs are on the rise, such as with Biogen in partnership with Eisai to co-develop and market Alzheimer's therapies, pooling resources and capabilities to drive faster entry into markets. These public-private initiatives mitigate financial risks and enhance resource sharing, de-risking drug development, and compress timelines. Commercially, they diversify the Alzheimer's drugs pipeline, stimulate investment from biotech and pharma, and boost regulatory and public trust in new medicines. These partnerships and funding influxes are accelerating disease-modifying treatments and underpinning a more innovation-driven Alzheimer's drugs market.

End User-Based Insights

Based on end user, the Alzheimer's drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest Alzheimer's drugs market share in 2024. Particularly in areas where hospital-based care is the main method of diagnosis and treatment initiation, hospital pharmacies distribute and oversee AD medications. Hospital pharmacies are essential resources for prescribing, dispensing, and advising patients and caregivers on therapeutic options due to the complexity of managing Alzheimer's disease, which calls for specialized neurologists or geriatricians. The sale of Alzheimer's medications in hospital pharmacies is influenced by reimbursement regulations and changing treatment recommendations. Hospitals continue to prescribe ChEIs as the first-line symptomatic treatments for mild to moderate AD. Because of its demonstrated effectiveness and tolerability, donepezil (Aricept), the most prescribed ChEI worldwide, is included in hospital formularies. Rivastigmine provides the dosing flexibility preferred in hospital settings where patient monitoring is practical. It is available as oral capsules and transdermal patches. Hospital pharmacies add value by providing medication counseling, adherence monitoring, and managing side effects-services critical in Alzheimer's treatment. Such programs differentiate hospital pharmacy offerings from retail outlets and support patient outcomes, potentially driving demand for specific formulations (e.g., rivastigmine patches for better compliance), thereby fueling the Alzheimer's drugs market growth.

The World Health Organization and Medicare are among the primary and secondary sources referred to while preparing the Alzheimer's drugs market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Alzheimer's Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Alzheimer's Drugs Market - Key Market Dynamics

  • 5.1 Alzheimer's Drugs Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Aging Population & Rising Alzheimer's Prevalence
    • 5.2.2 Improved Diagnostics & Early Detection
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Disease-Modifying Therapies (DMTs)
  • 5.4 Market Opportunities
    • 5.4.1 Combination Therapies and Adjunct Treatments
  • 5.5 Future Trends
    • 5.5.1 Public-Private Collaborations and Funding Growth
  • 5.6 Impact of Drivers and Restraints:

6. Alzheimer's Drugs Market - Global Market Analysis

  • 6.1 Alzheimer's Drugs Market Revenue (US$ Million), 2021-2031
  • 6.2 Alzheimer's Drugs Market Forecast Analysis

7. Alzheimer's Drugs Market Analysis - by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Overview
    • 7.1.2 Cholinesterase Inhibitors: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 NMDA Receptor Antagonists
    • 7.2.1 Overview
    • 7.2.2 NMDA Receptor Antagonists: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Combination Drugs
    • 7.3.1 Overview
    • 7.3.2 Combination Drugs: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Alzheimer's Drugs Market Analysis - by End User

  • 8.1 Hospital Pharmacies
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacies
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Alzheimer's Drugs Market - Geographical Analysis

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 North America Alzheimer's Drugs Market Overview
    • 9.2.2 North America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.2.2.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.2.2.1.1 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.2.2.2 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.2.3 North America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 United States: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.1.1 United States: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.1.1.1 United States: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.1.2 United States: Alzheimer's Drugs Market Breakdown, by End User
      • 9.2.3.2 Canada: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.2.1 Canada: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.2.1.1 Canada: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.2.2 Canada: Alzheimer's Drugs Market Breakdown, by End User
      • 9.2.3.3 Mexico: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.3.1 Mexico: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.2.3.3.1.1 Mexico: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.2.3.3.2 Mexico: Alzheimer's Drugs Market Breakdown, by End User
  • 9.3 Europe
    • 9.3.1 Europe Alzheimer's Drugs Market Overview
    • 9.3.2 Europe: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.3.2.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.3.2.1.1 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.3.2.2 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.3.3 Europe: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 Germany: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.1.1.1 Germany: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.1.2 Germany: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.2 United Kingdom: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.2.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.2.1.1 United Kingdom: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.2.2 United Kingdom: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.3 France: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.3.1 France: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.3.1.1 France: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.3.2 France: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.4 Italy: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.4.1 Italy: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.4.1.1 Italy: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.4.2 Italy: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.5 Spain: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.5.1 Spain: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.5.1.1 Spain: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.5.2 Spain: Alzheimer's Drugs Market Breakdown, by End User
      • 9.3.3.6 Rest of Europe: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.6.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.3.3.6.1.1 Rest of Europe: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.3.3.6.2 Rest of Europe: Alzheimer's Drugs Market Breakdown, by End User
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Alzheimer's Drugs Market Overview
    • 9.4.2 Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.4.2.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.4.2.1.1 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.4.2.2 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.4.3 Asia Pacific: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 China: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.1.1 China: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.1.1.1 China: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.1.2 China: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.2 Japan: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.2.1 Japan: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.2.1.1 Japan: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.2.2 Japan: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.3 India: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.3.1 India: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.3.1.1 India: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.3.2 India: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.4 Australia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.4.1 Australia: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.4.1.1 Australia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.4.2 Australia: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.5 South Korea: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.5.1 South Korea: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.5.1.1 South Korea: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.5.2 South Korea: Alzheimer's Drugs Market Breakdown, by End User
      • 9.4.3.6 Rest of APAC: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.6.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.4.3.6.1.1 Rest of APAC: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.4.3.6.2 Rest of APAC: Alzheimer's Drugs Market Breakdown, by End User
  • 9.5 Middle East and Africa
    • 9.5.1 Middle East and Africa Alzheimer's Drugs Market Overview
    • 9.5.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.5.2.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.5.2.1.1 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.5.2.2 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.5.3 Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 Saudi Arabia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.1.1.1 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.1.2 Saudi Arabia: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.2 South Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.2.1 South Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.2.1.1 South Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.2.2 South Africa: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.3 United Arab Emirates: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.3.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.3.1.1 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.3.2 United Arab Emirates: Alzheimer's Drugs Market Breakdown, by End User
      • 9.5.3.4 Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.4.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.5.3.4.1.1 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.5.3.4.2 Rest of Middle East and Africa: Alzheimer's Drugs Market Breakdown, by End User
  • 9.6 South and Central America
    • 9.6.1 South and Central America Alzheimer's Drugs Market Overview
    • 9.6.2 South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
      • 9.6.2.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Drug Class
        • 9.6.2.1.1 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Cholinesterase Inhibitors
      • 9.6.2.2 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by End User
    • 9.6.3 South and Central America: Alzheimer's Drugs Market - Revenue and Forecast Analysis - by Country
      • 9.6.3.1 Brazil: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.1.1.1 Brazil: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.1.2 Brazil: Alzheimer's Drugs Market Breakdown, by End User
      • 9.6.3.2 Argentina: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.2.1 Argentina: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.2.1.1 Argentina: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.2.2 Argentina: Alzheimer's Drugs Market Breakdown, by End User
      • 9.6.3.3 Rest of South and Central America: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.6.3.3.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Drug Class
          • 9.6.3.3.1.1 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by Cholinesterase Inhibitors
        • 9.6.3.3.2 Rest of South and Central America: Alzheimer's Drugs Market Breakdown, by End User

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Market Share Analysis, 2024

11. Industry Landscape

  • 11.1 Overview
  • 11.2 New Product Development and Approvals
  • 11.3 Partnerships
  • 11.4 Other Business Strategies

12. Company Profiles

  • 12.1 Novartis AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Daiichi Sankyo Co Ltd
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Pfizer Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Merck & Co Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Biogen Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Merz Pharma GmbH & Co KGaA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Eli Lilly and Co
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Otsuka Pharmaceuticals Co Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 AbbVie Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Alzheimer's Drugs Market Segmentation
  • Table 2. Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million)
  • Table 3. Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million)
  • Table 4. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 5. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 6. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 7. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 8. North America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 9. North America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 10. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 11. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 12. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 13. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 14. United States: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 15. United States: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 16. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 17. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 18. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 19. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 20. Canada: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 21. Canada: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 22. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 23. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 24. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 25. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 26. Mexico: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 27. Mexico: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 28. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 29. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 30. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 31. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 32. Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 33. Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 34. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 35. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 36. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 37. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 38. Germany: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 39. Germany: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 40. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 41. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 42. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 43. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 44. United Kingdom: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 45. United Kingdom: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 46. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 47. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 48. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 49. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 50. France: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 51. France: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 52. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 53. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 54. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 55. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 56. Italy: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 57. Italy: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 58. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 59. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 60. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 61. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 62. Spain: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 63. Spain: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 64. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 65. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 66. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 67. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 68. Rest of Europe: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 69. Rest of Europe: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 70. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 71. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 72. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 73. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 74. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 75. Asia Pacific: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 76. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 77. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 78. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 79. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 80. China: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 81. China: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 82. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 83. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 84. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 85. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 86. Japan: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 87. Japan: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 88. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 89. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 90. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 91. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 92. India: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 93. India: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 94. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 95. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 96. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 97. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 98. Australia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 99. Australia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 100. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 101. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 102. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 103. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 104. South Korea: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 105. South Korea: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 106. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 107. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 108. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 109. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 110. Rest of APAC: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 111. Rest of APAC: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 112. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 113. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 114. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 115. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 116. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 117. Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 118. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 119. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 120. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 121. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 122. Saudi Arabia: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 123. Saudi Arabia: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 124. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 125. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 126. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 127. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 128. South Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 129. South Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 130. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 131. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 132. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 133. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 134. United Arab Emirates: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 135. United Arab Emirates: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 136. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 137. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 138. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 139. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 140. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 141. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 142. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 143. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 144. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 145. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 146. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 147. South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 148. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 149. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 150. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 151. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 152. Brazil: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 153. Brazil: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 154. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 155. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 156. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 157. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 158. Argentina: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 159. Argentina: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 160. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Drug Class
  • Table 161. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Drug Class
  • Table 162. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by Cholinesterase Inhibitors
  • Table 163. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cholinesterase Inhibitors
  • Table 164. Rest of South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2024 (US$ Million) - by End User
  • Table 165. Rest of South and Central America: Alzheimer's Drugs Market - Revenue Forecast, 2025-2031 (US$ Million) - by End User
  • Table 166. Heat Map Analysis by Key Players
  • Table 167. Glossary of Terms, Global Alzheimer's Drugs Market

List Of Figures

  • Figure 1. Alzheimer's Drugs Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Alzheimer's Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Alzheimer's Drugs Market Share (%) - by Drug Class (2024 and 2031)
  • Figure 6. Cholinesterase Inhibitors: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. NMDA Receptor Antagonists: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Combination Drugs: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Others: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Alzheimer's Drugs Market Share (%) - by End User (2024 and 2031)
  • Figure 11. Hospital Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Retail Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Online Pharmacies: Alzheimer's Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Alzheimer's Drugs Market Breakdown by Region, 2024 and 2031 (%)
  • Figure 15. North America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 16. North America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. United States: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Canada: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Mexico: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Europe: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 21. Europe: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 22. Germany: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. United Kingdom: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. France: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. Italy: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 26. Spain: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Rest of Europe: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Asia Pacific: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 29. Asia Pacific: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 30. China: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Japan: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. India: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. Australia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 34. South Korea: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Rest of APAC: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. Middle East and Africa: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 37. Middle East and Africa: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 38. Saudi Arabia: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 39. South Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 40. United Arab Emirates: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 41. Rest of Middle East and Africa: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 42. South and Central America: Alzheimer's Drugs Market - Revenue, 2021-2031 (US$ Million)
  • Figure 43. South and Central America: Alzheimer's Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 44. Brazil: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Argentina: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. Rest of South and Central America: Alzheimer's Drugs Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 47. Company Market Share Analysis, 2024